

CORRECTION

Open Access



Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice

Sylvia Grünewald^{1,2†}, Maria Stecklum^{3†}, Manuel Rizzo¹, Jonathan Rathjens⁴, Lukas Fiebig¹ and Dieter Zopf^{1,2*}

Correction: European Journal of Medical Research (2023) 28:147

<https://doi.org/10.1186/s40001-023-01099-2>

In the original publication of the article, the order of affiliations was incorrect. The corrected order of affiliations is given in this Correction article. The abbreviations “conc Concentration” and “Y Tyrosine” were included inadvertently though they are not abbreviated in text. The abbreviations of Concentration and Tyrosine were removed. The original article has been corrected.

contribute to the inhibition of colorectal tumors in mice. Eur J Med Res. 2023;28:147. <https://doi.org/10.1186/s40001-023-01099-2>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published: 24 June 2023

Reference

1. Grünewald S, Stecklum M, Rizzo M, Rathjens J, Fiebig L, Zopf D. Effects of regorafenib on the mononuclear/phagocyte system and how these

[†]Sylvia Grünewald and Maria Stecklum contributed equally to this work.

The original article can be found online at <https://doi.org/10.1186/s40001-023-01099-2>.

*Correspondence:

Dieter Zopf

dieter.zopf@nuvisan.com

¹ Bayer AG, Berlin, Germany

² Present Address: Nuvisan ICB GmbH, Berlin, Germany

³ EPO Berlin-Buch GmbH, Berlin, Germany

⁴ Chrestos Concept GmbH & Co. KG, Essen, Germany

